M&A Deal Summary |
|
---|---|
Date | 2019-03-05 |
Target | iovera |
Sector | Medical Products |
Buyer(s) | Pacira |
Sellers(s) | NMT Capital |
Deal Type | Add-on Acquisition |
Deal Value | 220M USD |
Advisor(s) | Perella Weinberg Partners (Financial) Latham & Watkins (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2006 |
Sector | Life Science |
Employees | 711 |
Revenue | 675M USD (2023) |
Pacira is a specialty pharmaceutical company dedicated to advancing and improving postsurgical outcomes for acute care practitioners and their patients. Pacira’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension). EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Pacira was founded in 2006 and is based in Tampa, Florida.
DEAL STATS | # |
---|---|
Overall | 1 of 2 |
Sector (Medical Products) | 1 of 1 |
Type (Add-on Acquisition) | 1 of 2 |
State (California) | 1 of 1 |
Country (United States) | 1 of 2 |
Year (2019) | 1 of 1 |
Size (of disclosed) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2021-10-11 |
Flexion Therapeutics
Burlington, Massachusetts, United States Flexion Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, local non-opioid therapies for the treatment of patients with musculoskeletal conditions, including osteoarthritis (OA), postsurgical pain and low back pain. Flexion Therapeutics is based in Burlington, Massachusetts. |
Buy | - |
Category | Private Equity Firm |
---|---|
Size | Small |
Type | Sector Agnostic |
NMT Capital is a private equity firm focused on tech-oriented growth industries. Areas of interest include medical devices, diagnostics, biotechnology, specialty pharmaceutical, drug discovery tools, software, communications, information technology, and advanced materials. NMT Capital is based in Quincy, Massachusetts.
DEAL STATS | # |
---|---|
Overall | 10 of 10 |
Sector (Medical Products) | 5 of 5 |
Type (Add-on Acquisition) | 9 of 9 |
State (California) | 2 of 2 |
Country (United States) | 8 of 8 |
Year (2019) | 1 of 1 |
Size (of disclosed) | 1 of 4 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2016-03-24 |
Magellan Biosciences
Chelmsford, Massachusetts, United States Magellan Biosciences, Inc. is a developer and manufacturer of FDA-cleared products for the testing of blood to diagnose lead poisoning in children and adults. |
Sell | - |